5:59 PM
 | 
Jan 14, 2013
 |  BC Extra  |  Clinical News

Eisai's farletuzumab misses in ovarian cancer

Eisai Co. Ltd. (Tokyo:4523; Osaka:4523) said IV farletuzumab plus carboplatin and taxane chemotherapy missed the primary endpoint of improving progression-free survival (PFS) vs. placebo plus carboplatin and taxane chemotherapy in the Phase III FAR 131 trial...

Read the full 169 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >